Molecular mechanisms of Th17 plasticity in MS

MS 中 Th17 可塑性的分子机制

基本信息

项目摘要

DESCRIPTION (provided by applicant): Multiple sclerosis (MS) and its mouse model (experimental autoimmune encephalomyelitis; EAE) are autoimmune diseases of the central nervous system initiated and propagated by auto-reactive CD4+ T cells. Two subsets of CD4+ T cells, Th1 and Th17 cells have been implicated in the pathogenicity of autoimmune diseases and in particular MS. However, the relative contribution of myelin specific Th1 and Th17 cells in the development of central nervous system (CNS) autoimmunity remains controversial since neither IL-17F, IL- 17A, nor IFN-g deficient mice are fully protected from the development of CNS autoimmunity. In contrast, IL- 23p19- and IL-23 receptor (IL-23R) deficient mice are highly resistant to the development of EAE. Furthermore, in inflamed tissues of patients with autoimmune diseases, Th cells co-expressing IFN-g and IL-17 have been identified in significant number. Their increase frequency in target tissues during autoimmunity suggests an important role of these cells in the disease process. However, the genesis, stability and function of these cells in autoimmunity remain enigmatic. We have determined that most CNS-infiltrating T cells during the course of EAE express the IL-23R irrespective of their cytokine production (IL-17 and/or IFN-g) because they originate from Th17 cells. We further show that IL-23 plays a critical role in Th17 plasticity as it promotes the emergence of IL-17+ IFN-g+ T cells (Th17/g) from Th17 cells. Although Th17/g cells expressed T-bet, IFN-g production in these cells was not controlled by T-bet or other IFN-g-promoting transcription factors. In contrast, we identified AhR as a key transcription factor driving the production of IFN-g by Th17 cells in response to IL-23. We have also confirmed the importance of IL-23 for the generation of these cells in human CD4+ T cells. In addition, we have initiated a genome-wide analysis of DNase hypersensitivity sites in human Th1 and Th17 cells subsets using Solexa sequencing. Our results show that we can identify transcription factors binding sites and distinguish epigenetic marks in individual T cell subsets using this technique. In this proposal, we will test our overarching hypothesis that TH17/g cells are pathogenic cells in CNS-specific autoimmunity, are driven by IL-23 through an AhR-dependent mechanism and present with selective genetic alterations in MS patients. Together the completion of this study will not only delineate the function of Th17/g cells in autoimmunity but also determine the mechanisms by which these cells are generated and can be regulated in mice and humans.
描述(由申请人提供):多发性硬化症(MS)及其小鼠模型(实验性自身免疫性脑脊髓炎; EAE)是由自身反应性CD 4 + T细胞引发和传播的中枢神经系统自身免疫性疾病。两个亚群的CD 4 + T细胞,Th 1和Th 17细胞已被牵连在自身免疫性疾病,特别是MS的致病性。然而,髓鞘特异性Th 1和Th 17细胞在中枢神经系统(CNS)自身免疫性的发展中的相对贡献仍然存在争议,因为无论是IL-17 F,IL-17 A,也没有IFN-γ缺陷的小鼠是完全保护免受CNS自身免疫性的发展。相比之下,IL-23 p19和IL-23受体(IL-23 R)缺陷型小鼠对EAE的发展具有高度抗性。此外,在患有自身免疫性疾病的患者的发炎组织中,已经鉴定出大量共表达IFN-g和IL-17的Th细胞。在自身免疫过程中,它们在靶组织中的频率增加表明这些细胞在疾病过程中的重要作用。然而,这些细胞在自身免疫中的起源、稳定性和功能仍然是个谜。我们已经确定,在EAE过程中,大多数CNS浸润性T细胞表达IL-23 R,而不管它们的细胞因子产生(IL-17和/或IFN-g)如何,因为它们起源于Th 17细胞。我们进一步表明IL-23在Th 17可塑性中起关键作用,因为它促进IL-17+ IFN-g+ T细胞(Th 17/g)从Th 17细胞中出现。虽然Th 17/g细胞表达T-bet,但这些细胞中IFN-g的产生不受T-bet或其他IFN-g促进转录因子的控制。相比之下,我们确定AhR作为一个关键的转录因子驱动IFN-γ的生产由Th 17细胞响应IL-23。我们还证实了IL-23对于在人CD 4 + T细胞中产生这些细胞的重要性。此外,我们已经启动了一个全基因组分析的DNA酶超敏位点在人类Th 1和Th 17细胞亚群使用Solexa测序。我们的研究结果表明,我们可以确定转录因子的结合位点,并区分表观遗传标记在个别T细胞亚群使用该技术。在这项提案中,我们将测试我们的总体假设,即TH 17/g细胞是CNS特异性自身免疫中的致病细胞,由IL-23通过AhR依赖性机制驱动,并在MS患者中存在选择性遗传改变。总之,这项研究的完成不仅将描绘Th 17/g细胞在自身免疫中的功能,而且还将确定这些细胞在小鼠和人类中产生和调节的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Estelle Bettelli其他文献

Estelle Bettelli的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Estelle Bettelli', 18)}}的其他基金

Development and functions of tissue resident memory T cells during EAE
EAE 期间组织驻留记忆 T 细胞的发育和功能
  • 批准号:
    10549845
  • 财政年份:
    2022
  • 资助金额:
    $ 37.83万
  • 项目类别:
Development and functions of tissue resident memory T cells during EAE
EAE 期间组织驻留记忆 T 细胞的发育和功能
  • 批准号:
    10440905
  • 财政年份:
    2022
  • 资助金额:
    $ 37.83万
  • 项目类别:
Mechanisms of suppression of effector T cells in EAE
EAE 中效应 T 细胞的抑制机制
  • 批准号:
    9916611
  • 财政年份:
    2020
  • 资助金额:
    $ 37.83万
  • 项目类别:
Regulation of pathogenic T cells in EAE
EAE 中致病性 T 细胞的调节
  • 批准号:
    10058806
  • 财政年份:
    2016
  • 资助金额:
    $ 37.83万
  • 项目类别:
Molecular mechanisms of Th17 plasticity in MS
MS 中 Th17 可塑性的分子机制
  • 批准号:
    8591063
  • 财政年份:
    2013
  • 资助金额:
    $ 37.83万
  • 项目类别:
Molecular mechanisms of Th17 plasticity in MS
MS 中 Th17 可塑性的分子机制
  • 批准号:
    8999022
  • 财政年份:
    2013
  • 资助金额:
    $ 37.83万
  • 项目类别:
Function of a novel subset of dendritic cells in EAE
EAE 中树突状细胞的新亚群的功能
  • 批准号:
    8469105
  • 财政年份:
    2012
  • 资助金额:
    $ 37.83万
  • 项目类别:
Function of a novel subset of dendritic cells in EAE
EAE 中树突状细胞的新亚群的功能
  • 批准号:
    8386516
  • 财政年份:
    2012
  • 资助金额:
    $ 37.83万
  • 项目类别:
Interplay Between Pathogenic and Regulatory T Cells in EAE
EAE 中致病性 T 细胞和调节性 T 细胞之间的相互作用
  • 批准号:
    8113645
  • 财政年份:
    2008
  • 资助金额:
    $ 37.83万
  • 项目类别:
Interplay Between Pathogenic and Regulatory T Cells in EAE
EAE 中致病性 T 细胞和调节性 T 细胞之间的相互作用
  • 批准号:
    7943400
  • 财政年份:
    2008
  • 资助金额:
    $ 37.83万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
    Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
  • 批准号:
    23H02155
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
  • 批准号:
    10788032
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
  • 批准号:
    23K14742
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
  • 批准号:
    10864719
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
  • 批准号:
    10586562
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
  • 批准号:
    10593224
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
  • 批准号:
    23K06589
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
  • 批准号:
    10623380
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
  • 批准号:
    10735148
  • 财政年份:
    2023
  • 资助金额:
    $ 37.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了